• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Stroke Heroes 2016
The American Heart Association/American Stroke Association's Puget Sound Division, along with our sponsor Medtronic, congratulates the honorees for this year's Stroke Hero Awards. We had amazing stories sent to us. Thank you to all of you who submitted a nomination. Here are some of the inspiring individuals honored this year as a Stroke Hero. AMY MOORE, Stroke Survivor Amy is described as a truly an inspiring person who has never let her stroke stop her from accomplishing her goals. Her stroke was diagnosed at six months of age and left her legally blind. Amy learned Braille during her first two years of high school an...
Source: Healthy Living - The Huffington Post - July 12, 2016 Category: Consumer Health News Source Type: news